Gossamer Bio/$GOSS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gossamer Bio
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Ticker
$GOSS
Sector
Primary listing
Employees
145
Headquarters
Website
Gossamer Bio Metrics
BasicAdvanced
$524M
-
-$0.61
1.96
-
Price and volume
Market cap
$524M
Beta
1.96
52-week high
$3.60
52-week low
$0.66
Average daily volume
4.5M
Financial strength
Current ratio
4.402
Quick ratio
4.114
Long term debt to equity
-437.988
Total debt to equity
-439.918
Interest coverage (TTM)
-13.28%
Profitability
EBITDA (TTM)
-145.286
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-344.81%
Operating margin (TTM)
-361.91%
Effective tax rate (TTM)
2.49%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-29.63%
Return on equity (TTM)
-783.37%
Valuation
Price to revenue (TTM)
12.849
Price to book
-11.24
Price to tangible book (TTM)
-11.24
Price to free cash flow (TTM)
-3.349
Free cash flow yield (TTM)
-29.86%
Free cash flow per share (TTM)
-0.681
Growth
Revenue change (TTM)
-58.02%
Earnings per share change (TTM)
63.31%
3-year earnings per share growth (CAGR)
-41.43%
What the Analysts think about Gossamer Bio
Analyst ratings (Buy, Hold, Sell) for Gossamer Bio stock.
Bulls say / Bears say
Enrollment completed for the Phase 3 PROSERA study on June 11, 2025, with 390 Functional Class II/III PAH patients, speeding the timeline for topline pivotal data to February 2026.
Seralutinib received Orphan Drug Designation from Japan’s Ministry of Health, Labour and Welfare for PAH on January 31, 2025, potentially speeding regulatory review and extending market exclusivity.
Reported $258 million in cash, cash equivalents, and marketable securities as of March 31, 2025, providing funding into late 2026 for ongoing Phase 3 clinical programs.
Cash, cash equivalents, and marketable securities fell 17% quarter-over-quarter to $212.9 million as of June 30, 2025, reflecting higher cash burn from late-stage development.
Collaboration revenue dropped to $11.5 million for Q2 2025 from $95.8 million in Q2 2024 due to the absence of one-time license payments, highlighting revenue volatility and dependence on milestone-driven income.
Research and development expenses rose 19% year-over-year to $41.6 million in Q2 2025 from $35.1 million, increasing cash burn and the possibility of needing external financing.
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
Gossamer Bio Financial Performance
Revenues and expenses
Gossamer Bio Earnings Performance
Company profitability
Gossamer Bio News
AllArticlesVideos
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension
Business Wire2 weeks ago
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
Business Wire3 weeks ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Gossamer Bio stock?
Gossamer Bio (GOSS) has a market cap of $524M as of October 12, 2025.
What is the P/E ratio for Gossamer Bio stock?
The price to earnings (P/E) ratio for Gossamer Bio (GOSS) stock is 0 as of October 12, 2025.
Does Gossamer Bio stock pay dividends?
No, Gossamer Bio (GOSS) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next Gossamer Bio dividend payment date?
Gossamer Bio (GOSS) stock does not pay dividends to its shareholders.
What is the beta indicator for Gossamer Bio?
Gossamer Bio (GOSS) has a beta rating of 1.96. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.